Philips and InSightec partner to expand access to MR-guided focused ultrasound for incisionless neurosurgery
17 December 2020 - 8:00PM
December 17, 2020
Companies to develop compatibility of Philips’ MR Ingenia 3.0T
and 1.5T systems with the InSightec Exablate Neuro platform
Amsterdam, the Netherlands and Haifa, Israel – Royal
Philips (NYSE: PHG, AEX: PHIA), a global leader in health
technology and InSightec, a global healthcare company focused on
the therapeutic power of acoustic energy, today announced a
collaboration to expand access to MR-guided focused ultrasound for
incisionless neurosurgery. By developing compatibility between
Philips’ advanced MR systems and the Exablate Neuro platform from
InSightec, the two companies will support expanded access to
MR-guided focused ultrasound for the treatment of Essential Tremor
and other neurological disorders. The expansion of access to this
innovative treatment option has the potential to significantly
improve the patient and staff experience, enhance health outcomes
and lower the cost of care.
Essential Tremor is a neurological condition that typically
causes shaking of the hands, head and voice, and may also cause
shaking of the legs and trunk. The tremor begins mildly and
progresses over time, and in some patients, is severe enough to
interfere with daily activities, such as personal care, eating or
getting dressed. Essential Tremor is one of the most common
movement disorders in the world [1]. MR-guided focused ultrasound
uses high-intensity sound waves, guided by magnetic resonance
imaging, to target and treat the area of the brain responsible for
the tremor. The incisionless treatment option is often performed in
an outpatient setting, with many patients showing immediate tremor
relief with minimal complications.
“As a leading innovator in MR imaging to support precise
diagnosis and targeted therapies, we continue to expand the role of
MR in providing precision guidance for minimally invasive therapy
solutions into new treatment areas,” said Arjen Radder, General
Manager for MR at Philips. “By partnering with InSightec we are
expanding access to Philips’ advanced MR capabilities to a wider
range of healthcare providers, including neurosurgery practices
both in-hospital and in outpatient settings, as well as the global
research community. Together, we aim to advance towards clear care
pathways with predictable outcomes for every patient.”
“InSightec is committed to expanding patient access for
MR-guided focused ultrasound, which is rapidly being adopted as a
standard of care worldwide for treating Essential Tremor, as well
as continuing to develop a research pipeline for the treatment of
many other disorders,” said Maurice R. Ferré MD, InSightec CEO and
Chairman of the Board of Directors. “Partnering with Philips will
help increase adoption of our innovative technology to transform
patient care.”
The partnership will involve the development of compatibility
between the InSightec Exablate Neuro platform and Philips’ MR
Ingenia Elition 3.0T, Ingenia 3.0T and Ingenia 1.5T systems. This
includes the Ambition 1.5T MR, the industry’s first and only
commercially available fully sealed magnet for more productive,
helium-free operations [2]. Philips’ MR therapy portfolio also
includes its Ingenia MR-OR intraoperative MR for use during
neurosurgical procedures, as well as its leading MR-only
radiotherapy applications, which enable clinicians to quickly
execute complete imaging protocols for prostate, female pelvis,
brain, head and neck, and spine.
The parties expect market introduction for the compatible
systems in 2023 with offerings available for both existing and new
customers.
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938289/[2]
Compared to the Ingenia 1.5T ZBO magnet.
For further information, please contact:
Mark GrovesPhilips Global Press OfficeTel.: +31 631 639
916E-mail: mark.groves@philips.com
Lyndsay IsaksenG&S Business Communications for
InSightecTel.: +1 917 595 3032 E-mail:
lisaksen@gscommunications.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2019 sales of EUR 19.5 billion and
employs approximately 81,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
About InSightec
InSightec is a global healthcare company creating the next
generation of patient care by realizing the therapeutic power of
acoustic energy. The company’s Exablate® Neuro platform focuses
sound waves, guided by MRI, to provide tremor relief to patients
with Essential Tremor and Tremor-dominant Parkinson’s Disease.
Research for future applications in the neuroscience space is
underway in partnership with leading academic and medical
institutions. InSightec is headquartered in Haifa, Israel, and
Miami, with offices in Dallas, Shanghai and Tokyo. For more
information, please visit: www.insightec.com.
- The Philips MR Ingenia Ambition 1.5T
- MR-guided focused ultrasound for incisionless neurosurgery
- InSightec logo
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2024 to May 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From May 2023 to May 2024